After AstraZeneca, some quit J&J COVID-19 trial in Spain

Modesto Morganelli
Settembre 16, 2020

Phase II trials are created to test which dose and schedule of a vaccine generates the most antibodies while Phase III tests the vaccine's efficacy.

No major side effects, such as adverse reactions that require hospitalization, have been reported.

After the second dose, 36 percent of the age 18-to-64 group and 27 percent of the age 65-to-84 group reported fatigue. But some countries which have secured their own supplies through bilateral deals, including the United States, have said they will not join.

Johnson & Johnson's Belgian Janssen unit began Phase II trials of its COVID-19 vaccine on 190 people in Spain on Monday with those tests due to conclude on September 22.

Pfizer had said the US Food and Drug Administration (FDA) will consider issuing an emergency use authorization of a vaccine if it sees strong enough safety and efficacy data in a subset of the trial volunteers. Last week, nine pharma companies, including Astra-Zeneca and Pfizer, pledged to rigorously vet any vaccine, but the researchers said that missing from the joint statement was a promise to share more critical details about their research.

'It is a must to release this data'.

The British-Swedish pharmaceutical company's clinical trial was suspended last week after one volunteer was hospitalised and reportedly diagnosed with transverse myelitis, which causes inflammation in the spinal cord and is associated with viral infections.

According to WHO, there are 35 candidate vaccines around the world now undergoing clinical evaluation.

Shares of AstraZeneca AZN.L inched higher in early trade on Monday as the optimism spurred by the British drugmaker's resumption of clinical trials for its COVID-19 vaccine candidate outweighed official weekend moves to cut USA drug prices. That is expected to trigger in turn an immune response so the body can fight off any future COVID-19 infection.

COVID-19 vaccines being developed in China might be available for use by the general public as early as November, according to a top scientist with the Chinese Center for Disease Control and Prevention (CDC).

Volunteers given either the low or medium dose generated not just antibodies against the virus but specifically neutralizing antibodies, meaning they stop the virus from infecting human cells.

The trial compares effects of two doses of the vaccine candidate jointly developed by Pfizer and BioNTech, to two shots of placebo.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE